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ttp://dx.doi.org/10.1016/j.ajpath.2014.04.002Hepatocellular carcinoma (HCC), the third most common cause of cancer-related deaths worldwide,
lacks effective medical therapy. Large subsets of HCC demonstrate Wnt/b-catenin activation, making
this an attractive therapeutic target. We report strategy and characterization of a novel small-molecule
inhibitor, ICG-001, known to affect Wnt signaling by disrupting b-catenineCREB binding protein in-
teractions. We queried the ZINC online database for structural similarity to ICG-001 and identiﬁed
PMED-1 as the lead compound, with 70% similarity to ICG-001. PMED-1 signiﬁcantly reduced b-
catenin activity in hepatoblastoma and several HCC cells, as determined by TOPﬂash reporter assay, with
an IC50 ranging from 4.87 to 32 mmol/L. Although no toxicity was observed in primary human hepa-
tocytes, PMED-1 inhibited Wnt target expression in HCC cells, including those with CTNNB1 mutations,
and impaired cell proliferation and viability. PMED-1 treatment decreased b-catenineCREB binding
protein interactions without affecting total b-catenin levels or activity of other common kinases. PMED-
1 treatment of Tg(OTM:d2EGFP) zebraﬁsh expressing GFP under the b-catenin/Tcf reporter led to a
notable decrease in b-catenin activity. The PMED effect on b-catenin signaling lasted from 12 to 24
hours in vitro and 6 to 15 hours in vivo. Thus, using a rapid and cost-effective computational meth-
odology, we have identiﬁed a novel and speciﬁc small-molecule inhibitor of Wnt signaling that may
have implications for HCC treatment. (Am J Pathol 2014, 184: 2111e2122; http://dx.doi.org/10.1016/
j.ajpath.2014.04.002)Supported by NIH grants 1R01DK062277, 1R01DK100287, and
1R01DK095498 (S.P.M.) and the University of Pittsburgh Endowed Chair
for Experimental Pathology (S.P.M.).
Disclosures: None declared.Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related deaths worldwide; due to lack of
effective treatment, HCC has a 90% fatality rate.1,2 Given
the current global burden of HCC, it is paramount to
develop an effective therapy against this disease. Surgical
resection and liver transplantation is a desirable therapeutic
approach because it may be curative and because it replaces
cirrhotic liver with disease-free donor liver.3,4 However,
because of shortage of donor organs, not every HCC patient
can receive a transplant. Given that HCC is a vascularized
tumor that derives its blood supply predominantly from the
hepatic artery, transarterial chemoembolization (TACE) has
been used to manage unresectable HCC.5 Because of
increased expression of various receptor tyrosine kinases
(RTKs), HCC has been shown to be somewhat susceptiblestigative Pathology.
.to multi-tyrosine kinase inhibitors.6e8 Indeed, sorafenib is
used to treat unresectable HCC, with some survival beneﬁt.9
Thus, current therapeutic strategies are beginning to take
advantage of speciﬁc pathways that are deregulated in HCC.
Wnt/b-catenin signaling is tightly regulated in the adult
liver, and its aberrant nuclear localization, which is multi-
factorial, is evident in a major subset of HCCs.10 Nuclear
b-catenin acts as a cofactor for the T-cell factor (TCF) family
of transcription factors and recruits histone acetyl trans-
ferases such as CREB-binding protein (CBP) to regulate the
expression of various target genes. Therapeutic efﬁcacy of
Delgado et alinhibiting b-catenin as a treatment strategy for this tumor type
has been shown both in vitro and in vivo.11e15 To date,
however, there are no clinically approved antieb-catenin
agents, and continued drug discovery and development are
needed. The small molecule (SM) ICG-001 is one such agent
that has shown to signiﬁcantly reduce b-catenin activity by
blocking b-catenineCBP interactions in tumor cell nuclei.16
The next-generation derivative PRI-724 is currently in phase
Ib/IIa clinical trials.17
By means of structure function similarity search to ICG-
001, we identiﬁed a novel SM inhibitor of b-catenin (PMED-
1) that blocks b-catenin signaling in multiple hepatoma cells,
thereby reducing their viability and proliferation, but is
nontoxic to primary human hepatocytes. PMED-1 lacks any
off-target effects on several common kinases and, like ICG-
001, it reduces b-catenineCBP interactions. In vivo, PMED-1
treatment of transgenic zebraﬁsh expressing GFP as a readout
of b-catenineTCF activity leads to a notable decrease in Wnt
signaling. Here, we highlight the relevance of cost-effective,
efﬁcacious, and simplistic similarity searches in streamlining
drug discovery and report discovery of a prospective SM that
may be effective against b-catenin in HCC cells.
Materials and Methods
Similarity Search
Morphological similarity is a similarity technique dependent
only on surface shape and charge characteristics of ligands.18
Morphological similarity is deﬁned as a Gaussian function of
the differences in the molecular surface distances of two
molecules at weighted observation points on a uniform grid.
The computed surface distances include both distances to the
nearest atomic surface and distances to donor and acceptor
surfaces. This function is dependent on the relative alignment
of the molecules, and consequently their alignment and
conformation must be optimized. The conformational opti-
mization problem is solved by fragmentation, conformational
search, alignment, and scoring, followed by incremental
reconstruction from high-scoring aligned fragments. The
alignment problem is addressed by exploiting the fact that
two unaligned molecules or molecular fragments that have
some degree of similarity will have some corresponding set
of observers making the same observations. Optimization of
the similarity of two unaligned molecules or molecular
fragments is enabled by ﬁnding similar sets of observers of
each molecule that form triangles of the same size.18
In Silico ADME and Toxicity Screening
Computational modeling tools were used to estimate ab-
sorption, distribution, metabolism, and excretion (ie, ADME)
and toxicity. For hits obtained from database screening, we
estimated bioavailability, aqueous solubility, and human in-
testinal absorption, using the ADME Suite 4.95 from Pharma
Algorithms-ACD/Labs (ACD/Labs; Advanced Chemistry2112Development, Toronto, ON, Canada). For toxicity pre-
dictions including cytochrome P450 (ie, CYP2D6) enzyme
inhibition potential, mutagenicity, and hERG inhibition of
the hits obtained from the database screening, we used Tox
Boxes version 2.9 (Pharma Algorithms-ACD/Labs). Lastly,
ACD/Blood-Brain Barrier permeation module (ADME Suite
4.95, Pharma Algorithms-ACD/Labs) was used to estimate
blood-brain barrier potential of the hits.
Cell Culture
Hep3B, HepG2, Snu-398 and Snu-449 cells were obtained
from ATCC (Manassas, VA). Huh-7 cells were obtained from
Japanese collection of research bioresources. HepG2 human
hepatoblastoma cells (3 105 and 4 104 cells per well for 6-
well and 24-well plates, respectively), Huh-7 human HCC
cells (2.5 105 and 4 104 cells per well), and Hep3B human
HCC cells (2.5  105 and 4  104 cells per well) from the
ATCC were cultured in Eagle’s minimal essential medium
(EMEM) supplemented with 10% fetal bovine serum (FBS)
(Atlanta Biologicals, Flowery Branch, GA). Snu-449 or Snu-
398 human HCC cells (3  105 and 4  104 cells per well)
were cultured in RPMI-1640 medium (ATCC) supplemented
with 10% FBS. Primary human hepatocytes for cell viability
studies were obtained from Dr. Stephen Strom (then principal
investigator of the Liver Tissue Cell Distribution Services,
University of Pittsburgh).
Human HCC Cell Culture and Transfection with Stable
b-Catenin Mutants
Hep3B (ATCC) human HCC cells were plated in 6-well
plates and cultured in EMEM (ATCC) supplemented with
10% FBS (Atlanta Biologicals) at 37C in a humidiﬁed 5%
CO2 atmosphere. A constitutively active b-catenin gene
resulting in a tyrosine-for-serine substitution (S33Y) was
kindly provided by Dr. Jian Yu (Department of Pathology,
Hillman Cancer Center, University of Pittsburgh). The cells
were grown to 90% conﬂuency, and 2 mg of wild-type and
S33Y b-catenin plasmid DNA was transfected with Lip-
ofectamine 2000 reagent (Life Technologies, Carlsbad, CA)
according to the manufacturer’s instructions. At 48 hours
after transfection, the cells were selected by multiple
passaging using 500 mg/mL geneticin (G418; Sigma-
Aldrich, St. Louis, MO) to generate stable transfected cell
lines. Wild-type or S33Y stably transfected Hep3B cells
(3  105 cells per well, 6-well plates; 4  104 cells per well,
24-well plates) were cultured for experiments in EMEM
supplemented with 10% FBS and 500 mg/mL G418.
b-CatenineTCF Luciferase Reporter Assay
TOPﬂash plasmid (Upstate; EMD Millipore, Billerica, MA)
has three copies of the Tcf/Lef sites upstream of a thymidine
kinase (TK) promoter and the ﬁreﬂy luciferase gene. HCC
cells were transfected simultaneously with Renillaajp.amjpathol.org - The American Journal of Pathology
Targeting b-Catenin in HCCreniformis luciferase (pRL-TK; Promega, Madison, WI) as a
transfection control and with TOPﬂash ﬁreﬂy luciferase
plasmids (Upstate; EMD Millipore) for b-catenineTCF
activity using FuGENE (Roche Diagnostics, Indianapolis,
IN) or Lipofectamine 2000 (Life Technologies) reagent. At
24 hours after transfection, cells were treated with dimethyl
sulfoxide (DMSO) (Thermo Fisher Scientiﬁc, Waltham,
MA), PMED-1 (ChemBridge, San Diego, CA), PMED-2
(ChemBridge), or ICG-001 for an additional 24 or 48
hours. Lysates were harvested using the dual-luciferase re-
porter assay system (Promega). Fireﬂy luciferase signals
were normalized to Renilla luciferase, and the ratio between
groups was compared by Student’s t-test to determine sig-
niﬁcance. P < 0.05 was considered signiﬁcant and P < 0.01
was considered highly signiﬁcant.
For time-course analysis, S33Y b-catenin stably trans-
fected Hep3B cells were cultured in serum-free EMEM
containing 500 mg/mL G418 for 4 hours before Lipofect-
amine 2000 (Life Technologies) cotransfection using
Renilla and TOPﬂash luciferase plasmids for 4 hours. Cells
were then exposed to EMEM containing 2% FBS and 500
mg/mL G418 overnight. On the next morning, cells were
serum-starved again for 4 hours to synchronize the cell
cycle and then were treated with either 0.05% DMSO or 25
mmol/L PMED-1 in EMEM containing 10% FBS and 500
mg/mL G418 for 3, 6, 9, 12, 18, 24, 36, or 48 hours before
harvest and analysis of samples for luciferase activity as
described above.
To determine the half-maximal inhibitory concentration
(IC50) of the drug required to reduce luciferase activity,
TOPﬂash reporter assay was performed. Snu-398, Snu-449,
Hep3B, and Huh-7 cells were plated in 96-well plates at
2  104 cells/well at 80% conﬂuence were transfected using
Lipofectamine 2000 with 100 ng of TOPﬂash ﬁreﬂy lucif-
erase and 10 ng of Renilla luciferase. Cells were treated
without or with serial dilutions in triplicate from 50 mmol/L to
1.5 mmol/L of PMED-1 in RPMI-1640 or EMEM medium
supplemented with FBS. PMED-1, dissolved in DMSO
(0.2% ﬁnal concentration), was administered in one dose at 4
hours after transfection. At 24 hours after treatment, cells
were harvested and lysed with passive lysis buffer (Prom-
ega). Luciferase assay was performed as described above,
and relative luciferase activity (ratio) was reported as fold
induction after normalization for transfection efﬁciency.
Western Blot Analysis
Whole-cell lysates were prepared using radioimmuno-
precipitation assay buffer containing 1% IgePAL CA-630,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate in
1 PBS after 24 hours of treatment with DMSO, PMED-1,
or ICG-001 SM at 25 mmol/L. The lysate (9 to 30 ng) was
run on a 7.5% polyacrylamide gel (Bio-Rad Laboratories,
Hercules, CA) at 60 V for 0.5 hours and then at 100 V for 1.5
hours. Gels were transferred onto a polyvinylidene ﬂuoride
membrane (Millipore) for 1 hour at 4C. Membranes wereThe American Journal of Pathology - ajp.amjpathol.orgblocked in 5% nonfat milk (LabScientiﬁc, Livingston, NJ)
in Blotto blocking reagent [0.15 mol/L NaCl, 0.02 mol/L
Tris at pH 7.5, 0.1% Tween in deionized water] for 1 hour at
room temperature. Primary antibodies for b-catenin (BD
Transduction Laboratories; BD Biosciences, San Jose, CA),
b-actin (Chemicon International; EMD Millipore), c-Myc
(Santa Cruz Biotechnology, Dallas, TX), cyclin D1
(Thermo Fisher Scientiﬁc), GAPDH (Santa Cruz Biotech-
nology), glutamine synthetase (Santa Cruz Biotechnology),
SMP30/regucalcin (Santa Cruz Biotechnology), and
VEGF-A (Santa Cruz Biotechnology) were diluted 1:1000,
1:2500, 1:200, 1:200, 1:800, 1:200, 1:200, and 1:200,
respectively, in 5% nonfat milk and Blotto reagent and were
incubated on membranes overnight at 4C. Membranes
were then washed in Blotto reagent for 1 hour at room
temperature before incubation of membranes with rabbit
(1:10,000), mouse (1:25,000), or goat (1:10,000) secondary
antibodies (EMD Millipore) in 1% nonfat milk and Blotto
reagent for 1 hour. Membranes were again washed in Blotto
reagent for 1 hour at room temperature before exposure to
SuperSignal West Pico or Femto chemiluminescent sub-
strate (Pierce; Thermo Fisher Scientiﬁc) for 1 to 2 minutes at
room temperature. The bands reﬂective of target proteins
were visualized by autoradiography.Immunoprecipitation
HepG2 cells treated with DMSO, 25 mmol/L PMED-1, or 25
mmol/L ICG-001 for 24 hours in 10-cm dishes. Whole-cell
lysates were prepared as described above, and 0.25 mg of
control mouse IgG (Santa Cruz Biotechnology) was used to
preclear lysates. b-Catenin monoclonal antibody (2 mg) (BD
Transduction Laboratories) was added to 500 mg of each
sample, which was incubated for 1 hour at 4C on a rocking
platform. Protein A/G PLUS agarose beads (20 mL) (Santa
Cruz Biotechnology) were added to each sample, which was
incubated overnight at 4C on a rocking platform. Samples
were then centrifuged at 10,000  g for 5 minutes and the
supernatant was removed. The bead pellet was then washed
with radioimmunoprecipitation assay buffer, followed by
three additional centrifugations and washes. After the ﬁnal
wash, bead pellets of each sample were resuspended in 40mL
of 2 SDS buffer (Bio-Rad Laboratories) and boiled at 95C
for 5 minutes. Samples were centrifuged one last time for 1
minute, and 20 mL of each sample was run on a 5% poly-
acrylamide gel (Bio-Rad Laboratories). Gel was run and
transferred as described above. The membrane was probed as
described above with primary antibody for CBP (A-22; Santa
Cruz Biotechnology) diluted 1:200 in 5% nonfat milk and
Blotto reagent and secondary anti-rabbit antibody diluted
1:10,000 in 1% nonfat milk and Blotto reagent. SuperSignal
West Pico chemiluminescent substrate (Thermo Fisher Sci-
entiﬁc) was used to develop the membrane as described
above. Densitometry was performed using ImageJ software
version 1.47 (NIH, Bethesda, MD).2113
Delgado et alMTT Assay for Toxicity
HCC cells were plated in 6-well plates and primary hepa-
tocytes were plated in 12-well plates for 24 hours. Cells
were then treated for 24 hours with DMSO, PMED-1, or
PMED-2. After incubation, cultures were changed into 1%
MTT (w/v) (Sigma-Aldrich) in PBS for 0.5 hours at 37C.
Cells were then lysed using room-temperature isopropanol.
Samples were read at 570 nm for colorimetric assessment.
Thymidine Incorporation Proliferation Assay
HepG2 or Snu-398 cells were plated in 6-well plates for
24 hours. Cells were then treated with DMSO or PMED-1
for 24 or 72 hours in the presence of 2.5 mCi of 50-[3H]
thymidine (PerkinElmer). Medium was aspirated, and
cells were washed with 1 PBS and incubated with 5%
trichloroacetic acid (Sigma-Aldrich) for 15 minutes at
4C. Next, plates were washed in running water and
placed to dry at 37C. Cells were then lysed in 0.33 N
NaOH for 20 minutes at room temperature. Samples were
combined with scintillation ﬂuid and measured in a
Beckman LS 6000 IC scintillation counter (Beckman
Coulter, Brea, CA).
Live Cell Imaging
HepG2 cells plated in 6-well plates were maintained in
medium supplemented with DMSO or 200 mmol/L PMED-1
under live-cell bright-ﬁeld imaging for 24 hours. Cells were2114imaged using a Nikon (Tokyo, Japan) Eclipse Ti live-cell
imaging system.
Immunoﬂuorescent Staining
HepG2 cells were plated 2  103 in 4-well chamber slides
for 24 hours, followed by 24 hours of DMSO or 25 mmol/L
PMED-1 treatment. For detection of cells in active cell
cycle (late G1, S, G2, and M phases), immunoﬂuorescence
for Ki-67 was performed. After DMSO or PMED-1 treat-
ment of HepG2 cells grown on chamber slides, cells were
ﬁxed in 4% paraformaldehyde. Wells were washed with
1 PBS and cells were permeabilized with 0.1% Triton-X
surfactant in PBS, followed by washes in PBS alone and
then with 0.5% bovine serum albumin in PBS (PBB).
Samples were blocked in 2% PBB for 1 hour, washed with
0.5% PBB, and incubated in 0.5% PBB containing primary
antibody for Ki-67 (Santa Cruz Biotechnology) at 1:100
for 1 hour. After a washing in 0.5% PBB, secondary
antibody anti-goat Alexa Fluor 555, diluted 1:1000 in
0.5% PBB, was applied to each well for 1 hour. Wells were
washed with 0.5% PBB, then with 1 PBS, and ﬁnally
were stained with Hoechst dye 33342 for 30 seconds.
Samples were coverslipped and imaged using a Nikon
Eclipse Ti live-cell imaging system.
Kinase Assays
Kinase assays were performed to assess activity of PMED-1
against AKT, protein kinase D (PKD), polo-like kinases 1 andFigure 1 Computational approach to identi-
fying SMs that inhibit Wnt signaling to affect
primary human hepatocytes and hepatic tumor
cells. A: A search of the ZINC version 8.0 database
lead-like subset identiﬁed 13,399 SMs structurally
similar to ICG-001. A similarity score of 70%
restricted the hits to 24 molecules, of which 20
passed in silico ADME/tox ﬁltering. B: Chemical
structure of ICG-001, PMED-1, and PMED-2. C:
HepG2 cells treated with 200 mmol/L PMED-1 or
PMED-2 for 24 hours exhibited a signiﬁcant
decrease in TOPﬂash luciferase reporter activity,
compared with 2% DMSO. D: Primary hepatocytes
treated with 2% DMSO or with 200 mmol/L PMED-1
or PMED-2 for 18 or 48 hours exhibited a signiﬁ-
cant decrease in viability by MTT assay only after
PMED-2 treatment. E: HepG2 cells treated with 200
mmol/L PMED-1 for 24 hours monitored by live-cell
imaging exhibit notable morphological changes
reminiscent of cell death as early as 3 hours after
treatment, compared with the 2% DMSO-treated
controls. F: HepG2 cells treated with 100 mmol/L
PMED-1 exhibited a signiﬁcant decrease in cell
viability as assessed by MTT assay, compared with
1% DMSO control. Data are expressed as means 
SD. *P < 0.05, **P < 0.01. Original magniﬁca-
tion, 200 (E).
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kinase (CAK). Opaque Small Volume plates from Greiner
Bio-One (Monroe, NC) were used: black for ﬂuorescence
polarization (FP) assay and white for time-resolved ﬂuores-
cence energy transfer (TR-Fret) assay. IMAP binding reagent,
binding buffer, terbium, peptide substrates (AKT: 5FAM-The American Journal of Pathology - ajp.amjpathol.orgGRPRTSSFAEG-COOH; PKD: 5FAM-KKLNRTLSVA-
COOH; Plk1 and CAK: 5FAM-KKRNRRLSVA-OH; Plk2:
5FAM-LKKLTRRPSFSAQ-COOH), and kinase reaction
buffers [10 mmol/L Tris-HCl at pH 7.2, 10 mmol/L MgCl2,
0.05% NaN3, 1 mmol/L dithiothreitol, and carrier (PKD,
AKT: 0.1% bovine serum albumin; Plk1, Plk2, CAK: 0.01%
Tween 20)] were purchased from Molecular Devices (Sun-
nyvale, CA). Active Plk1 and AKT were purchased from Cell
Signaling Technology (Danvers, MA), PKD and CAK from
Upstate (EMD Millipore), and Plk2 from Life Technologies.
ATPwas purchased fromGEHealthcare (Little Chalfont, UK)
and H89 from EMD Millipore.
Compounds were solubilized in DMSO to stock 10
mmol/L and then were diluted to 3 starting concentration
300 mmol/L (3% DMSO) and serially diluted in 3%
DMSOewater. In brief, 2 mL of 3 concentration substrate
and ATP in 2 complete reaction buffer was added to each
well of a microtiter plate. After 2 mL of 3 concentration
compound was added, 2 mL of 3 concentration enzyme in
1 complete reaction buffer was added to start the 6 mL
total volume kinase reaction. At the designated time, the
reaction was stopped by addition of binding solution con-
taining the binding reagent (FP assay) or binding reagent
and terbium (TR-Fret assay). Plates were read at excitation/
emission wavelengths Ex485/Em525 for FP or at Ex330/
Em490, 520 for TR-Fret on a Molecular Devices SpectraMax
M5. Speciﬁc ﬁnal reaction conditions were as follows.
IMAP-based Plk2 TR-Fret assay: 0.34 mU/mL Plk2; 550
nmol/L substrate peptide; 35 mmol/L ATP; 1% DMSO; 2.5
hours kinase reaction; 15 mL binding solution (70% A, 30%
B þ 1/600 binding reagent þ 1/400 terbium); 2 hours
binding incubation.
IMAP-based PKD FP assay: 0.06 mU/mL PKD; 100
nmol/L substrate peptide; 20 mmol/L ATP; 1% DMSO; 90
minutes kinase reaction; 18 mL binding solution (100% A þ
1/400 binding reagent); 2 hours binding incubation.
IMAP-based Plk1 TR-Fret assay: 0.034 mU/mL Plk1; 750
nmol/L substrate peptide; 25 mmol/L ATP; 1% DMSO; 3
hours kinase reaction; 18 mL binding solution (70% A, 30%
B þ 1/600 binding reagent þ 1/400 terbium); 5 hours
binding incubation.
IMAP-based CAK TR-Fret assay: 0.1 mU/mL CAK; 500
nmol/L substrate peptide; 25 mmol/L ATP; 1% DMSO; 3
hours kinase reaction; 12 mL binding solution (70% A, 30%
B þ 1/600 binding reagent þ 1/400 terbium).Figure 2 PMED-1 targets b-catenin signaling to affect cell proliferation
in HepG2 cells. A: HepG2 cells treated with 25 mmol/L PMED-1 for 24 hours
(white bars) exhibited a signiﬁcant decrease in TOPﬂash reporter activity,
but less so at 48 hours (black bars). B: Decrease in Ki-67þ cells (red) was
observed after treatment of HepG2 cells with 25 mmol/L PMED-1 for 24
hours, compared with 0.2% DMSO. C: DNA synthesis in HepG2 cells as
measured by [3H]thymidine incorporation exhibited a decrease in response
to 24 (white bars) or 72 (gray bars) hours of treatment with 25 mmol/L of
PMED-1, compared with 0.2% DMSO. D: Western blots using HepG2 cell
lysates reveal decreased b-catenin targets after 25 mmol/L PMED-1 treat-
ment. Data are expressed as means  SD. *P < 0.05, **P < 0.01. Original
magniﬁcation, 100 (B).
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Delgado et alIMAP-based AKT FP assay: 0.05 mU/mLAKT; 300 nmol/
L substrate peptide; 10 mmol/L ATP; 1% DMSO; 90 minutes
kinase reaction; 18 mL binding solution (75% A, 25% Bþ 1/
400 binding reagent); 45 minutes binding incubation.Zebraﬁsh Experiments
Embryos and adult ﬁsh were raised and maintained under
standard laboratory conditions.19 We used the Tg(OTM:-
d2EGFP) line to assess Wnt/b-catenin signaling in vivo.20
Five millimolar stock of PMED-1 and 10 mmol/L stock of
XAV939 (Cayman Chemical, Ann Arbor, MI) were pre-
pared in 1 DMSO and diluted to 15 and 10 mmol/L,
respectively, with egg water supplemented with 0.2 mmol/L
1-phenyl-2-thiourea (Sigma-Aldrich). As a control, 0.5%
DMSO solution in the egg water was used. For imaging,
embryos were anesthetized with 0.16 mg/mL tricaine
(Sigma-Aldrich) and mounted in egg water containing 3%
methyl cellulose (Sigma-Aldrich); a Leica M205 FA epi-
ﬂuorescence microscope (Leica Microsystems, Wetzlar,
Germany) was used to obtain bright-ﬁeld and GFP ﬂuo-
rescence images.2116Results
Similarity Search Identiﬁes SMs with 70% Structural
Similarity to ICG-001
Recognition of SMs by proteins is mediated largely by mo-
lecular surface complementarities. Structure-based approaches
to drug design use this as the fundamental guiding principle:
that is, closely related molecules will elicit similar activity in a
biological assay.21,22 Our starting point was to identify com-
pounds similar to ICG-00116 that could serve as structural
analogs by screening the lead-like subset of the ZINC 10
database (http://zinc.docking.org/subsets/lead-like, last
accessed February 15, 2010) (Figure 1A).23 This search
yielded 13,339 compounds, which were sorted by simi-
larity score. We retained 24 compounds with a similarity
score of 70% or greater.
ADME/Tox Predictions Identify 20 SMs That Pass in
Silico Screening
Because most failures in clinical trials result from issues
related to drug pharmacodynamics and pharmacokinetics, allFigure 3 IC50 of PMED-1 in various HCC cells
and the effect of PMED-1 on b-catenin signaling
and biology. AeD: IC50 was determined by
response of TOPﬂash reporter activity to PMED-1
treatment for 24 hours in Snu-449 (A), Snu-398
(B), Huh-7 (C), and Hep3B (D) cells. E: Relative
decrease in TOPﬂash reporter activity after 25
mmol/L PMED-1 treatment of various HCC cells for
24 hours. F: The most robust decrease in viability
as measured by MTT assay was observed in Snu-398
cells after 24 hours of 25 mmol/L PMED-1 treat-
ment. G: DNA synthesis as measured by [3H]
thymidine incorporation was signiﬁcantly reduced
in Snu-398 cells treated for 24 (white bars) or 72
(gray bars) hours with 25 mmol/L PMED-1,
compared with DMSO. H: Western blots using
whole-cell lysates from Snu-398, Snu-449, and
Hep3B cells treated with 25 mmol/L PMED-1 reveal
notable decreases in b-catenin downstream tar-
gets. Data are expressed as means  SD.
*P < 0.05, **P < 0.01.
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incorporate the evaluation of absorption, distribution, meta-
bolism, and excretion (ADME) and toxicological (Tox)
properties early in the discovery process, to mitigate this risk.
We therefore applied in silico ADME/Tox ﬁltering to prior-
itize compounds for purchase and further characterization. OfFigure 4 PMED-1 affects b-catenineCBP interactions but does not affect activ
from untreated HepG2 cells or HepG2 cells treated for 24 hours with either 2% DM
revealed signiﬁcantly less CBP pull-down with antieb-catenin antibody in cells t
(arbitrary units) for CBP are provided under the bands. BeK: Effect of H89 and P
PKD) or TR-Fret assay (CAK, Plk1, and Plk2). Three replicates are shown. B: H89 de
AKT activity. D: H89 decreases CAK activity. E: PMED-1 does not affect CAK activi
not affect PKD activity. H: H89 decreases Plk1 activity in a largely dose-dependent
log scale (0.097 mmol/L); however, no decrease was evident at higher concentrati
does not affect Plk2 activity. IP, immunoprecipitation.
The American Journal of Pathology - ajp.amjpathol.orgthe 24 compounds, 20 passed all of the ADME/Tox ﬁlters.
Based on the highest structural similarity to ICG-001, the top
two of these molecules, which we designated PMED-1 and
PMED-2, were selected for further characterization. The
structures of PMED-1, PMED-2, and ICG-001 are shown in
Figure 1B.ity of other common kinases. A: Western blot analysis of whole-cell lysates
SO, 25 mmol/L PMED-1, or 25 mmol/L ICG-001 used for immunoprecipitation
reated with PMED-1 or ICG-001, compared with DMSO. Densitometry values
MED-1 on activity of kinases as assessed by IMAP-based FP assay (AKT and
creases CAK activity in a dose-dependent manner. C: PMED-1 does not affect
ty. F: H89 decreases PKD activity at higher concentrations. G: PMED-1 does
manner. I: PMED-1 had an inhibitory effect on Plk1 up to 1 mmol/L on the
ons. J: H89 decreases Plk2 activity in a dose-dependent manner. K: PMED-1
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Without Toxicity to Primary Human Hepatocytes
To characterize the effectiveness and safety of the top two
SMs in inhibiting b-catenineTCF activity, we treated
HepG2 cells (a human hepatoblastoma cell line that harbors
constitutively active b-catenin because of a monoallelic
CTNNB1 exon-3 deletion) with a relatively high dose of
PMED-1 or PMED-2 (200 mmol/L) or with 2% DMSO for
24 hours.24 TOPﬂash luciferase reporter assay revealed a
signiﬁcant decrease in b-catenineTCF activity after PMED-
1 or PMED-2 treatment (Figure 1C). However, primary
human hepatocytes treated with the same high concentration
showed signiﬁcant toxicity as assessed by MTT assay only
to PMED-2 (200 mmol/L) after 48 hours (Figure 1D).
Because PMED-1 was nontoxic to human hepatocytes, we
next treated HepG2 cells with the same high concentration
(200 mmol/L) for durations up to 24 hours. This treatment
led to notable cell death, observed as clumping and round-
ing, compared with normally spread viable cells in DMSO-
treated cultures (Figure 1E). Furthermore, even at 100 mmol/
L the PMED-1 treatment of these cells for 24 and 48 hours
led to approximately 30% to 35% reduction in viability as
assessed by MTT assay (Figure 1F). These results indicate
that PMED-1, but not PMED-2, is selectively toxic to tumor
cells by affecting b-catenin activity.
PMED-1 Treatment Blocks Cell-Cycle Progression,
Proliferation, and Downstream Wnt Signaling in HepG2
Cells
Next, IC50 was assessed for PMED-1 in reducing TOPﬂash
reporter activity in HepG2 cells after 24 hours of treatment
with concentrations ranging from 200 mmol/L to 500 nmol/
L. A signiﬁcant decrease in TOPﬂash reporter activity was
observed only at a concentration of 25 mmol/L in this
human hepatoblastoma cell line (data not shown). Interest-
ingly, HepG2 cells treated with PMED-1 at 25 mmol/L
showed maximal decrease in TOPﬂash reporter activity at
24 hours, with some rebound at 48 hours (Figure 2A). To
determine the effect of blocking b-catenin activity on cell
proliferation, we ﬁrst assessed cells in active cell cycle by
Ki-67 immunoﬂuorescence. A notable decrease in the
number of Ki-67þ HepG2 cells was observed at 24 hours
after PMED-1 treatment (Figure 2B). To further address this
decrease in DNA synthesis over time, we performed a [3H]
thymidine incorporation assay, which revealed a persistentFigure 5 Efﬁcacy and duration of the effect of PMED-1 effect on b-catenin
Tg(OTM:d2EGFP) zebraﬁsh were treated with DMSO, XAV939, or PMED-1 for 15 ho
microscope. Shown are bright-ﬁeld images (top row), GFP ﬂuorescence images (m
cells with S33Y-b-catenin, treated with a single dose of PMED-1 at 25 mmol/L, exh
signiﬁcance at 18 and 24 hours after treatment, with rebound at 36 and 48 hours
Embryos strongly GFPþ [obtained from incrossing Tg(OTM:d2EGFP) zebraﬁsh] were
6, 12, or 24 hours later, and GFP expression was assessed under a ﬂuorescence m
expression is indicated at the lower left of each image. All images are dorsal view
vesicle; pf, pectoral ﬁn; re, retina; te, tectum.
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(Figure 2C). We next examined protein expression of b-
catenin and some of its targets in HepG2 cells at 24 hours
after 25 mmol/L PMED-1 treatment. Although no change in
total b-catenin was evident, a notable decrease in glutamine
synthetase, cyclin D1, c-Myc, and regucalcin protein levels
was evident (Figure 2D). Thus, PMED-1 treatment impedes
b-catenin signaling in HepG2 cells.
PMED-1 Affects b-Catenin Signaling to Impair Viability
and Proliferation in Multiple HCC Cell Lines
To determine IC50 of PMED-1 in reducing b-catenineTCF
activity inmultiple HCC cells, we treated Snu-449, Huh-7, and
Hep3B cells [which contain the wild-type b-catenin gene
(CTNNB1)] and Snu-398 cells (which harbor the S37C mu-
tation in CTNNB1) with a range of PMED-1 doses, as
described under Materials and Methods. Based on this anal-
ysis, PMED-1 had an IC50 of 4.87 mmol/L for Snu-449 cells,
8.25 mmol/L for Huh-7 cells, 25 mmol/L for Hep3B cells, and
32 mmol/L for Snu-398 cells (Figure 3, AeD). Next, to
compare the effect on b-catenin activity of PMED-1 at the
single dose of 25 mmol/L, we treated Snu-449, Hep3B, and
Snu-398 cells for 24 hours. A signiﬁcant decrease in TOPﬂash
reporter activity was evident in all cells, compared with
DMSO, albeit to varying extent in accord with the respective
IC50 values (Figure 3E). Intriguingly, the maximum effect of
PMED-1emediated decrease in cell viability by MTT assay
was evident in b-cateninemutated Snu-398 cells, demon-
strating their addiction to b-catenin signaling (Figure 3F);
however, decreased survival was evident in other HCC cells as
well (Figure 3F). A signiﬁcant decrease in [3H]thymidine
incorporation was also noted in Snu-398 cells treated for 24 or
72 hours with PMED-1 at 25 mmol/L (Figure 3G).
Whole-cell lysates from three HCC cell lines treated for
24 hours with 25 mmol/L PMED-1 were also assessed for
protein expression of b-catenin and its targets. A notable but
varying decrease in glutamine synthetase, cyclin D1, and
VEGF-A expression was observed in all cells, without any
inﬂuence on total b-catenin levels (Figure 3H). Thus,
PMED-1 effectively targets b-catenin activity in multiple
HCC cells to impair their viability and proliferation.
PMED-1 Inhibits b-CatenineCBP Interactions
To address the molecular basis of b-catenin inhibition by
PMED-1, we assessed b-catenineCBP interactions, becauseactivity in vivo and in vitro. A: GFPþ embryos obtained from outcrossing
urs (40 to 55 hpf), and GFP expression was assessed under a ﬂuorescence
iddle row), and merged images (bottom row). B: Stably transfected Hep3B
ibited a gradual decrease in TOPﬂash reporter activity; the decrease reached
. C: Epiﬂuorescence images of GFP expression in Tg(OTM:d2EGFP) embryos.
treated with DMSO, XAV939, or PMED-1 from 48 hpf. Embryos were harvested
icroscope. *P < 0.05. The proportion of embryos (n/N) exhibiting the GFP
, with anterior to the left. Scale bars: 100 mm (A and C). li, liver; ov, otic
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catenin inhibition by ICG-001.16 Indeed, treatment of
HepG2 cells with PMED-1 led to a notable decrease in
CBP-b-catenin as assessed by immunoprecipitation studies,
compared with DMSO treatment, although the effect was
less robust than with ICG-001 (Figure 4A). Similar modest
decreases in b-catenineCBP interactions were observed in
response to PMED-1 treatment of other cells, such as Snu-
398 cells (data not shown).
PMED-1 Does Not Inhibit Common Kinases
Next, we determined whether PMED-1 affects activity of
common kinases that could be the basis of some of the
observed biological effects. We compared the efﬁcacy of
PMED-1 to the multikinase inhibitor H89, which at high
doses can inhibit AKT, PKD, CAK, Plk1, and Plk2.25
Although dose-dependent inhibition of AKT (Figure 4B),
CAK (Figure 4D), PKD (Figure 4F), Plk1 (Figure 4H) and
Plk2 (Figure 4J) in response to H89 was observed, no in-
hibition was evident after PMED-1 treatment, especially at
25 mmol/L, which equates to 1.39 log mmol/L (Figure 4, C,
E, G, I, and K), a dose at which signiﬁcant decreases in b-
catenineTCF activity were observed. Intriguingly, low
doses of PMED-1 (2.5 to 1.0 log mmol/L, equating to
0.003 mmol/L to 0.09 mmol/L) led to an inverse decrease in
Plk1 kinase; at higher doses, however, this effect was lost
(Figure 4I). Thus, PMED-1 does not appear to have any
signiﬁcant off-target effects on these major kinases, espe-
cially at doses that effectively blocked b-catenin activity.
PMED-1 Impairs Wnt/b-Catenin Signaling in Vivo in
Zebraﬁsh Embryos
To determine whether PMED-1 can inhibit Wnt/b-catenin
signaling in vivo, we used the Tg(OTM:d2EGFP) zebraﬁsh
line, which expresses destabilized GFP under the promoter
containing six copies of Tcf/Lef binding sites.20 XAV939, a
known b-catenin inhibitor in zebraﬁsh, was used as a pos-
itive control.13 GFP expression was greatly reduced in 20/22
(91%) of the Tg(OTM:d2EGFP) embryos treated with
XAV939 for 15 hours, from 40 to 55 hours after fertilization
(hpf), and was weakly reduced in the remaining embryos,
compared with DMSO-treated controls (Figure 5A).
Importantly, GFP expression was greatly reduced in 12/25
(48%) of the embryos treated with PMED-1, compared with
the controls (Figure 5A). These data indicate the in vivo
efﬁcacy of PMED-1 as a Wnt/b-catenin signaling inhibitor.
Duration of Action of PMED-1 in Cell Culture and
in Vivo
To address the duration of the effect of PMED-1 on b-catenin
activity in cell culture and in vivo, we treated Hep3B cells that
were stably transfected with constitutively active S33Y-b-cat-
enin mutant. After a single-dose treatment of PMED-1 at 252120mmol/L, the cells were harvested at times ranging from 3 hours
to 48 hours for TOPﬂash reporter activity. As early as 6 hours
after PMED-1 treatment, a downward trend in TOPﬂash re-
porter activity was evident, compared with DMSO (Figure 5B).
Statistically signiﬁcant inhibition of b-catenin activity was
evident at 18 to 24 hours after PMED-1 treatment. Intriguingly,
at 36 hours TOPﬂash reporter activity was restored. Thus, a
single treatment with 25 mmol/L PMED-1 progressively de-
creases b-catenin activity from 6 to 24 hours in cell culture.
To determine how long PMED-1 can inhibit Wnt/b-cat-
enin signaling in vivo, we examined GFP expression in
Tg(OTM:d2EGFP) zebraﬁsh embryos at multiple time points
after a single PMED-1 treatment. To better reveal GFP
expression in the embryos, we used homozygous
Tg(OTM:d2EGFP) embryos, in which GFP expression is
stronger than in hemizygous embryos. GFPþ Tg(OTM:-
d2EGFP) embryos were treated with DMSO, XAV939, or
PMED-1 at 48 hpf and GFP expression was examined at 6,
12, or 24 hours later. At 54 hpf (6 hours after treatment), most
embryos treated with XAV939 (10/12) or PMED-1 (15/18)
exhibited reduced GFP expression, compared with controls
(Figure 5C). At 60 hpf (12 hours after treatment), GFP
expression was further reduced in XAV939-treated embryos,
and it continued to be reduced in PMED-1etreated embryos
(Figure 5C). Interestingly, at 72 hpf (24 hours after treat-
ment), GFP expression was signiﬁcantly restored in most
PMED-1etreated embryos (8/12), but it continued to be
suppressed in XAV939-treated embryos (Figure 5C). These
data indicate that the Wnt/b-catenin inhibitory activity of
PMED-1 lasts a shorter time than that of XAV939.Discussion
Currently, there is a lack of an effective medical therapy for
HCC. The multikinase inhibitor sorafenib has been shown to
improve overall survival of patients with advanced HCC.9,26
A distinct pathway active in signiﬁcant subsets of HCC pa-
tients is the Wnt/b-catenin signaling pathway.27 Activation
of b-catenin in HCC may lead to increased expression of
genes encoding for cyclin D1, glutamine synthetase, survi-
vin, c-Myc, EpCAM, and VEGF-A, which contribute to
HCC by regulating cell proliferation, survival, metabolism,
cancer stem cell expansion, and angiogenesis.12,28e33 Thus,
inhibition of b-catenin in a subset of HCC is expected to be of
signiﬁcant therapeutic relevance. However, there are no
effective inhibitors of b-catenin approved for clinical use,
although its inhibition in HCC is being increasingly dis-
cussed,10,34 thus making it an interesting target for drug
design.
Developing a drug from bench to bedside is an arduous
and slow process. High-throughput screens assess SMs for
potential efﬁcacy against a desired target; however, because
there is little to no selectivity or speciﬁcity in these screens,
the eventual effect may be due to an off-target effect.35 The
intention in such studies is to discover a molecule that willajp.amjpathol.org - The American Journal of Pathology
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knowledge of the mechanism), which can then be tested for
its efﬁcacy in vivo. We took a novel approach by basing our
drug discovery on ICG-001, a previously established SM
inhibitor of b-catenineCBP interactions. Based on the
premise of structureefunction similarity, we found that
PMED-1, a SM resembling the structure of ICG-001, shows
similar function in inhibiting b-catenin in multiple HCC cell
lines, although at a higher concentration. Like ICG-001,
PMED-1 inhibits b-catenineCBP interactions and thus
impedes downstream signaling. CBP is a histone acetyl
transferase and interacts with b-catenin in the nucleus once
it has been activated and has been shown to be critical for b-
cateninedependent target gene expression.16 Importantly,
PMED-1 did not show any off-target kinase inhibition. We
also checked the quality of PMED-1 by high-performance
liquid chromatography and nuclear magnetic resonance, to
determine whether any contaminant or degradation product
could be responsible for inhibiting b-catenineTCF activity.
The results showed that the PMED-1 used in our studies
was >95% pure (data not shown).
PMED-1 successfully targeted b-catenin signaling in a
hepatoblastoma cell line with exon-3 deletion in b-catenin
gene (HepG2) and a HCC cell line with b-catenin point
mutation (Snu-398) with an IC50 of 25 mmol/L and 32 mmol/
L, respectively. Several downstream targets of b-catenin
signaling were suppressed, which led to impaired tumor cell
proliferation and survival. Additional HCC cells with wild-
type b-catenin gene were more responsive to inhibitory ef-
fect of PMED-1, although these cells showed less addiction
to Wnt signaling for their growth and survival. Indeed, Snu-
398 cells showed a robust decrease in tumor cell survival
and proliferation on PMED-1 treatment. An in vitro time
course showed that the antieb-catenin effect of a single
dose of PMED-1 lasts up to 24 hours. This was in contrast
to ICG-001, which has a prolonged effect lasting several
days (unpublished data; M.K.). Interestingly, the effect of a
single dose of PMED-1 on cell proliferation or viability was
evident at 72 hours, indicating that even transient interrup-
tion of b-catenin signaling cascade may impair downstream
biological processes for a longer duration. Indeed, similar
prolonged biological effects of transient b-catenin suppres-
sion by other modalities such as peptide nucleic acid anti-
sense on cell proliferation and survival have been
reported.12 How PMED-1 is metabolized and inactivated
remains a topic of ongoing investigation.
A major limitation of the present study is the issue of
solubility of PMED-1. As a hydrophobic SM, PMED-1
could be dissolved only in DMSO, which limited our ability
to perform in vivo studies in orthotopic or xenograft models
of HCC in mice. However, we demonstrated its in vivo ef-
ﬁcacy in a zebraﬁsh model. In this model, similar to cell
culture, PMED-1 exhibited peak antieb-catenin activity
from 5 to 15 hours after treatment, further evidence of a
relatively short half-life. This short half-life most likely
explains the restoration of b-catenineTCF-driven EGFPThe American Journal of Pathology - ajp.amjpathol.orgexpression in approximately 50% of the zebraﬁsh embryos
at 15 hours after PMED-1 treatment and in 67% of the
embryos at 24 hours. Although we did not directly inves-
tigate the mechanism of PMED-1 in vivo, it likely also in-
volves blockade of b-catenineCBP interactions. Additional
studies will be necessary to address whether chemical or
structural modiﬁcations can alter the solubility and meta-
bolism of PMED-1 for improved drug delivery.
Ultimately, the present study demonstrates the practical
application of in silico screening in effective identiﬁcation
of a speciﬁc molecule against b-cateninedriven HCC, with
future therapeutic implications. This technique led us to
identify PMED-1, which is similar to its parent compound
ICG-001 in some ways and different in others. PMED-1 is
especially different from ICG-001 in having a less robust b-
catenin inhibitory effect and in having a shorter duration of
action. However, these seemingly negative attributes of
PMED-1 could make this agent more suitable for use in
certain speciﬁc applications, such as locoregional therapies.
This may be especially relevant, because PMED-1 is quite
hydrophobic, a property that may allow for it to be retained
in the tumor microenvironment. Similarly, a shorter half-life
of the agent in vivo theoretically lessens the systemic
adverse effects. Further studies will be critical to address
such important questions relevant to PMED-1.
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